|
|
|
|
LEADER |
00000cam a2200000Mu 4500 |
001 |
EBOOKCENTRAL_ocn908075810 |
003 |
OCoLC |
005 |
20240329122006.0 |
006 |
m o d |
007 |
cr |n||||||||| |
008 |
150509s2011 pau o 000 0 eng d |
040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OCLCQ
|d ZCU
|d MERUC
|d ICG
|d OCLCO
|d OCLCF
|d OCLCQ
|d OCLCO
|d OCLCQ
|d DKC
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCL
|
019 |
|
|
|a 923527933
|a 994988543
|
020 |
|
|
|a 9781451165685
|
020 |
|
|
|a 1451165684
|
029 |
1 |
|
|a DEBBG
|b BV044057457
|
035 |
|
|
|a (OCoLC)908075810
|z (OCoLC)923527933
|z (OCoLC)994988543
|
050 |
|
4 |
|a RC451.4.A5C523 2011
|
082 |
0 |
4 |
|a 618.97/68918
|
049 |
|
|
|a UAMI
|
100 |
1 |
|
|a Salzman, Carl.
|
245 |
1 |
0 |
|a Clinical Geriatric Psychopharmacology.
|
250 |
|
|
|a 4th ed.
|
260 |
|
|
|a Philadelphia :
|b Wolters Kluwer Health,
|c 2011.
|
300 |
|
|
|a 1 online resource (718 pages)
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
588 |
0 |
|
|a Print version record.
|
505 |
0 |
|
|a Clinical Geriatric Psychopharmacology; Preface; Contributing Authors; Contents; Part I: Overview; 1 Older Americans and Mental Illness; Characteristics of U.S. Elderly; Population Heterogeneity; Chronic Illness and Comorbidity; Normal Age-Related Change; Benefits of Treatment; Rates of Mental Disorders; Dementia; Delirium; Depression; Anxiety; Schizophrenia; Sleep Problems; Alcohol Dependence and Abuse; Problems in the Use of Psychotropic Drugs; Nature of the Problem; Treatment Modalities; Risk Versus Benefit Considerations; Treatment Settings; Managed Care; Primary Care; Nursing Homes.
|
505 |
8 |
|
|a Clinician Misperceptions in Use of Psychotropic Medications2 Drug Prescribing, Adverse Reactions, and Compliance in Elderly Patients; Prescription-Drug Use Concerns; Over-the-Counter Medication Concerns; Prevelance of Psychotropic Drug Use; Psychotropic Prescribing Practices in Selected Settings; Hospital Inpatients; Nursing Home Residents; Approaches to Improving Prescription Practices; Prescribing Regulations in Nursing Homes; Advantages of the Institutional Setting; Educational Approaches to Prescribing in Nursing Homes; Collaborative Care Models.
|
505 |
8 |
|
|a Drug Use Review and ''Appropriateness'' MeasuresMedication Withdrawal; Common Side Effects of Psychotropic Drug Use; Sedation; Confusion; Orthostatic Hypotension; Falls and Fractures; Cardiac Side Effects; Extrapyramidal Symptoms; Ageism, Polypharmacy, and Adverse Drug Reactions; Nutritional Status and Drug Effects; Compliance; Overall Compliance and Older Patients; Types of Noncompliance; Techniques for Improving Compliance; Other Psychosocial Variables; Decreasing Multiple Medications; Conclusion; 3 The Cost of Psychotropic Drug Use for the Elderly.
|
505 |
8 |
|
|a 2003 Medicare Prescription Drug LegislationRise in Prescription Drug Costs; Demographics of Medication Use; Effect of Prescription Drug Coverage on Use; Medicare Beneficiaries With and Without Prescription Drug Coverage; Psychotropic Drug Utilization; Psychotropic Drug Costs and Compromised Patients; Conclusions; Part II: The Aging Process and Response to Psychotropic Drugs; 4 Neurotransmission in the Aging Central Nervous System; The Neurotransmission Process; Effect of Age on Neurotransmitters; Norepinephrine; Dopamine; Serotonin; Acetylcholine; Benzodiazepine-GABA Receptor Complex.
|
505 |
8 |
|
|a GlutamateEffect of Psychotropic Drugs on Neurotransmisison; Age-Related Central Nervous System Alterations in Receptor Sensitivity and Psychotropic Drug Effects; 5 Kinetics and Dynamics of Psychotropic Drugs in the Elderly; Basic Pharmacokinetic Principles and the Aging Process; Absorption; Distribution; Protein Binding; Steady-State Plasma Levels and Drug Accumulation; Pharmacodynamics and Aging; Pharmacokinetics of Specific Drug Groups; Sedatives, Hypnotics, and Anxiolytics; Antidepressants; Lithium; Neuroleptics; Using Pharmacokinetic Information in Prescribing Psychotropic Drugs.
|
500 |
|
|
|a Absorption.
|
520 |
|
|
|a Thoroughly updated for its Fourth Edition, this volume is the most authoritative clinical reference on the pharmacologic treatment of psychiatric disorders in elderly patients. This edition provides complete information on new psychotropic drugs, new uses for established drugs, and clinically relevant advances in the neurosciences. Four new chapters cover genes, pharmacokinetics, and their impact on prescribing; new cognitive-enhancing strategies and drugs; late-life depression and physical illness; and depression and cardiac disease in late life. The book offers detailed guidelines-including.
|
590 |
|
|
|a ProQuest Ebook Central
|b Ebook Central Academic Complete
|
650 |
|
0 |
|a Geriatric psychopharmacology.
|
650 |
|
6 |
|a Psychopharmacologie gériatrique.
|
650 |
|
7 |
|a Geriatric psychopharmacology
|2 fast
|
758 |
|
|
|i has work:
|a Clinical geriatric psychopharmacology (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCGVVqqjG3kRwGJcccPcbgq
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
776 |
0 |
8 |
|i Print version:
|a Salzman, Carl.
|t Clinical Geriatric Psychopharmacology.
|d Philadelphia : Wolters Kluwer Health, ©2011
|z 9780781743808
|
856 |
4 |
0 |
|u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=3418524
|z Texto completo
|
938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL2032605
|
994 |
|
|
|a 92
|b IZTAP
|